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Abstract The bioflavonoid silymarin is found to potently
suppress both nuclear factor kappa-B (NF-UB)-DNA binding
activity and its dependent gene expression induced by okadaic
acid in the hepatoma cell line HepG2. Surprisingly, tumor
necrosis factor-K-induced NF-UB activation was not affected by
silymarin, thus demonstrating a pathway-dependent inhibition by
silymarin. Many genes encoding the proteins of the hepatic acute
phase response are under the control of the transcription factor
NF-UB, a key regulator in the inflammatory and immune
reactions. Thus, the inhibitory effect of silymarin on NF-UB
activation could be involved in its hepatoprotective property.
z 1998 Federation of European Biochemical Societies.
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1. Introduction
In£ammatory reactions are triggered in many liver diseases,
as the consequence of the introduction of a toxin, drug or
infectious agent, to induce a repair process and to reestablish
the original functions of the hepatic tissue. However, a failure
to eliminate the noxious agent, in addition to the disruption of
regulatory mechanisms, such as the ones controlling the res-
olution of the acute phase response, may lead to the develop-
ment of chronic liver in£ammation.
An in£ammatory response depends on the de novo synthe-
sis of many mediators, including regulatory proteins, which
are produced upon an inducible gene expression. This gene
expression is controlled by transcription factors which are
activated by external in£ammatory stimuli. The transcription
factor nuclear factor kappa-B (NF-UB) has been suggested to
play a key role in these reactions. The activation of NF-UB is
itself induced by a variety of stimuli such as proin£ammatory
cytokines, phorbol esters, bacterial or viral products, phos-
phatase inhibitors, oxidants and ultraviolet radiation [1]. Evi-
dence of the involvement of reactive oxygen intermediates in
NF-UB activation has been presented as well [2]. Upon acti-
vation, the inhibitory protein IUB, sequestrating NF-UB in the
cytosol, is phosphorylated and degraded. The inducible phos-
phorylation of IUB proteins generally occurs on two serines in
their NH2-terminal domain [3]. However, in certain cells
under certain conditions, tyrosine phosphorylation of IUB
has been demonstrated [4,5]. Following the IUB release, NF-
UB translocates into the nucleus and binds to speci¢c DNA
motifs in the promoter region of genes whose product is im-
plicated in in£ammatory and immune responses [1]. Accord-
ingly, controlling NF-UB activation has become a pharmaco-
logical challenge, particularly in the chronic in£ammatory
disorders [6].
Silymarin is a £avonoid blend extracted from the seeds of
Lady’s thistle (Silybum marianum (Gaertn.)). Its pharmacolog-
ically active components are the £avonolignans silibinin and
its derivatives with silibinin as the primary element of the
blend (Fig. 1). Silymarin has been clinically used for its bene-
¢cial e¡ects on various liver diseases such as alcohol or drug
intoxication, mushroom poisoning and viral hepatitis [7],
whose pathogenesis involves an in£ammatory response. The
properties underlying its hepatoprotective e¡ects are thought
to be multiple: free radical scavenging activity, prevention of
glutathione oxidation and depletion, membrane stabilizing ef-
fect, inhibition of arachidonic acid metabolism and increased
protein synthesis by activation of RNA polymerase I [8^11].
The objective of the present study was to investigate
whether silymarin can block NF-UB activation and its de-
pendent gene expression induced by various stimuli in the
human hepatoblastoma cell line HepG2 and to show its po-
tential to inhibit the in£ammatory response in liver disorders.
2. Materials and methods
2.1. Materials
Eagle’s Minimum Essential Medium and non-essential amino acids
were obtained from Life Technologies (Gaithersburg, MD, USA). L-
Glutamine, sodium pyruvate, penicillin and streptomycin were ob-
tained from UCSF Cell Culture Facilities (San Francisco, CA,
USA). Okadaic acid (ammonium salt) (OA) was obtained from Alexis
(San Diego, CA, USA). Recombinant human tumor necrosis factor
(TNFK) was generously provided by Genentech (South San Francis-
co, CA, USA). Silymarin and lipopolysaccharide from Escherichia coli
serotype 055:B5 (LPS) were obtained from Sigma (St. Louis, MO,
USA) as were all other chemicals unless speci¢ed. Silymarin was dis-
solved in dimethylsulfoxide (DMSO) at concentrations a thousand
times the ¢nal concentrations, so that DMSO ¢nal concentration
was equal to or less than 0.1%.
2.2. Cell culture
The HepG2 cell line (HB 8065; American Type Culture Collection,
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Rockville, MD, USA), a human hepatoblastoma-derived cell line, was
cultured in Eagle’s Minimum Essential Medium containing 2 mM L-
glutamine, 1.5 g/l sodium bicarbonate, Earle’s salts, 1 mM sodium
pyruvate, 0.1 mM non-essential amino acids, 100 U/ml penicillin
and 100 Wg/ml streptomycin and supplemented with 10% de¢ned fetal
bovine serum (Hyclone, Logan, UT, USA). Cells were seeded at a
density of 40^100 000 cells/cm2 in 6-well plates (Falcon, Becton Dick-
inson Labware, Franklin Lakes, NJ, USA), containing 3 ml of me-
dium and grown in a humidi¢ed air atmosphere with 5% CO2 at 37‡C.
2.3. Preparation of nuclear extracts from HepG2
HepG2 cells (500 000 cells/cm2) were treated separately with 25 ng/
ml TNFK and 100 ng/ml LPS for 1 h or with 0.6 WM OA for 30 min.
Silymarin (0.5^25 Wg/ml) was added to the medium 24 h earlier. Nu-
clear extracts were then prepared according to Olnes and Kurl [12]
with slight modi¢cations. In brief, cells were washed with ice-cold
phosphate bu¡ered saline (PBS), harvested, centrifuged and resus-
pended in 400 Wl of a freshly prepared bu¡er A (10 mM HEPES
(pH 7.9), 10 mM KCl, 1 mM MgCl2, 0.5 mM EDTA (pH 8.0), 0.1
mM EGTA (pH 8.0), 5% (v/v) glycerol, 1 mM DTT, 0.5 mM PMSF,
5 Wg/ml leupeptin, 1 mM benzamidine and 1% (w/v) aprotinin) and
kept on ice for 15 min before the addition of 25 Wl of 10% (v/v) NP-
40. Incubation was continued on ice for an additional 5 min, followed
by centrifugation for 30 s at 15 000Ug at 4‡C. The pellet was sus-
pended in 100 Wl of bu¡er C (20 mM HEPES (pH 7.9), 400 mM
NaCl, 1 mM EDTA (pH 8.0), 1 mM EGTA (pH 8.0), 20% (v/v)
glycerol, 1 mM DTT, 1 mM PMSF, 10 Wg/ml leupeptin, 1 mM ben-
zamidine and 1% (v/v) aprotinin), incubated at 4‡C for 15 min, vor-
texed for 15 min and ¢nally centrifuged for 20 min (15 000Ug at 4‡C).
The supernatant (nuclear extract) was collected and frozen at 380‡C.
Protein concentration was measured using the Bio-Rad Protein Assay
I (Bio-Rad, Richmond, CA, USA).
2.4. Electrophoretic mobility shift assay (EMSA)
EMSAs were performed as previously described [13]. Equal
amounts of the nuclear protein extracts (7.5^10 Wg) were incubated
with the NF-UB speci¢c 32P-labeled double-stranded oligonucleotide
(Promega, Madison, WI, USA). Oligonucleotides were labelled with
[Q-32P]ATP using T4 polynucleotide kinase (New England Biolabs,
Beverly, MA, USA) and then puri¢ed on Chroma-Spin-10-TE (Clon-
tech, Palo Alto, CA, USA). Binding reactions were carried out at
room temperature for 30 min, in a 20-Wl volume containing the nu-
clear extract, 4 Wl of 5U binding bu¡er (125 mM HEPES (pH 7.9),
5 mM EDTA (pH 8.0), 2.5 M NaCl, 5 mM DTT and 50% (v/v)
glycerol), 2 Wg poly(dI-dC)Wpoly(dI-dC) (Pharmacia, Piscataway, NJ,
USA) and about 0.05 pmol of the labeled oligonucleotide (50^100 000
cpm). The binding speci¢city was determined using the unlabeled
wild-type probe (100-fold in excess) to compete with the labeled oli-
gonucleotide. A cold mutant oligonucleotide (100-fold in excess) (San-
ta Cruz Biotechnology, Santa Cruz, CA, USA) was added in some
experiments to the reaction to further determine the binding speci¢c-
ity. Next, the samples were loaded on a 6% non-denaturing polyacryl-
amide gel and run with a 0.5U TBE bu¡er, pH 8.0. Dried gels were
autoradiographed overnight at room temperature.
2.5. Cell transfection and reporter assay
HepG2 were plated at 40 000 cells per cm2 in 12-well plates, and 24
h later transiently co-transfected with the plasmids pGL3-4UB-Luc
[14] and pRL-TK (plasmid reference containing a Renilla luciferase
gene driven by a minimal thymidine kinase promoter) using Superfect
reagent (Qiagen, Valencia, CA, USA) according to the manufacturer’s
protocol. Brie£y, the transfection mixture containing 0.3 Wg of both
plasmids was mixed with the Superfect reagent (10 Wl/Wg of plasmid
DNA) and subsequently added to the cell culture. The medium was
changed after 2 h and cells were allowed to recover for 24 h prior to
medium supplementation with silymarin. Afterwards, transiently co-
transfected HepG2 cells were separately treated with di¡erent concen-
trations of OA and TNFK. Cell lysis was performed 8 h after the
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Fig. 1. Chemical structure of silibinin, the main constituent found
in silymarin extract. C25H22O10, FW 482.4, 2-[2,3-dihydro-3-(4-hy-
droxy-3-methoxyphenyl)-2-(hydroxymethyl)-1,4-benzodioxin-6-yl]-2,3-
dihydro-3,5,7-trihydroxy-4H-1-benzopyran-4-one (CAS # 22888-70-
6).
Fig. 2. Silymarin inhibits OA- and LPS- but not TNFK-induced
NF-UB activation in HepG2 cells. EMSA analysis of HepG2 nuclear
extracts after stimulation with OA (0.6 WM) for 30 min (A), LPS
(100 ng/ml) (B) and TNFK (25 ng/ml) (C) for 2 h. Silymarin (0.5^25
Wg/ml) was added to the culture medium 24 h before the treatments.
Representative experiments are shown. A: In lane 1, ‘*’ represents
the addition of a large excess of unlabelled UB-speci¢c oligonucleo-
tide for competition purposes. A, B and C: ‘x’ represents NF-UB
complex and ‘o’ non-speci¢c complexes.
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treatments and luciferase activities were measured using the Dual-
Luciferase Reporter Assay System (Promega, Madison, WI, USA)
with an LKB/Wallac luminometer 1250 (Wallac, Gaithersburg, MD,
USA). The Dual-Luciferase system is based on the subsequent meas-
urement of ¢re£y (from pGL3-4UB-Luc) and Renilla (from pRL-TK)
luciferase activities in the same tube with the same extract. The ¢re£y
luciferase activity was normalized in that system with the Renilla
luciferase activity to correct for di¡erences in transfection e⁄ciency.
3. Results
3.1. Silymarin inhibits OA- and LPS- but not TNFK-induced
NF-UB binding activity in HepG2 cells
The HepG2 cell line was chosen to study NF-UB activation
in response to various stimuli. This cell line has been inten-
sively investigated; it exhibits morphological and biochemical
characteristics of normal human hepatocytes [15,16]. The £a-
vonoid silymarin was added to the culture medium of HepG2
cells for 24 h. Then, the cells were challenged with various
stimuli inducing NF-UB activation. After stimulation with OA
(0.6 WM) for 30 min, nuclear extracts were prepared and NF-
UB DNA binding activity was assessed by EMSA (Fig. 2A).
The addition of 25 Wg/ml of silymarin to unchallenged cells
caused a diminution of the basal or constitutive NF-UB DNA
binding activity. A signi¢cant inhibitory e¡ect was observed
with silymarin concentrations above 12.5 Wg/ml, while a sily-
marin concentration of 25 Wg/ml completely abolished OA-
induced NF-UB activation. In addition, the inhibitory e¡ect
of silymarin was speci¢c on the OA-induced NF-UB DNA
binding activity. In other words, the AP-1, SRF and C/
EBPL DNA binding activities were not a¡ected by silymarin
(data not shown).
Treatment of HepG2 cells with LPS (100 ng/ml) for 1 h also
induced NF-UB activation and was completely inhibited when
the cells were pre-incubated with 25 Wg/ml of silymarin (Fig.
2B).
In contrast, TNFK-induced NF-UB DNA binding activity
was not altered by silymarin (Fig. 2C). Silymarin was ine⁄-
cient as well with respect to phorbol myristate acetate (PMA)-
induced NF-UB activation (data not shown).
3.2. Okadaic acid, tumor necrosis factor-K and
lipopolysaccharide induce NF-UB-dependent gene
expression in HepG2 cells
Transiently co-transfected HepG2 cells were exposed to OA
(25^100 nM) or TNFK (1^10 ng/ml) for 8 h. Dual-Luciferase
assays performed after these treatments demonstrated the in-
ducing capacity of these stimuli to activate NF-UB (Fig. 3).
While TNFK induced NF-UB-dependent gene expression in a
concentration-dependent manner, OA (50 nM) caused a
nearly two-fold increase which was not enhanced with higher
concentrations. Treatments with the PMA induced NF-UB-
dependent gene expression in a similar pattern to TNFK,
whereas LPS responded in the same manner as OA (data
not shown). The speci¢city of the induction was tested in a
separate set of experiments using a plasmid containing mu-
tated UB motifs (data not shown).
3.3. Silymarin potently inhibits OA- and but not TNFK-induced
NF-UB-dependent gene expression in HepG2 cells
To con¢rm the previous results that silymarin not only in-
hibits NF-UB DNA binding activity but also suppresses the
induction of NF-UB-dependent gene expression, HepG2 cells
were transiently co-transfected with both pGL3-4UB-Luc and
pRL-TK plasmids. After a period of 24 h with varying con-
centrations of silymarin, HepG2 cells were challenged for 8 h
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Fig. 3. Okadaic acid and tumor necrosis factor-K induce NF-UB-de-
pendent gene expression in HepG2. OA, TNFK and LPS were
added to the culture medium for 8 h prior to the cell lysis. The
Dual-Luciferase assay was performed and luciferase activity ex-
pressed as relative to that of the control (untreated cells). The data
are presented as means (with values on top of the bars) from at
least 2 independent experiments, each performed in duplicate.
Fig. 4. Silymarin inhibits OA- but not TNFK-induced NF-UB-de-
pendent gene expression in HepG2 cells. HepG2 cells were transi-
ently co-transfected, the medium supplemented with silymarin (5^25
Wg/ml) for 24 h and then treated separately with OA (50 nM) (A)
and TNFK (2 ng/ml) (B) for 8 h. The cells were subsequently har-
vested and luciferase activity reported as relative to that of the con-
trol and values are the mean þ S.E.M. from at least 3 independent
experiments, each carried out in duplicate (A and B).
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using OA (50 nM) or TNFK (2 ng/ml) independently (Fig. 4).
The extent of the inductions achieved with these inducers were
between two and three times higher than that of the control.
As observed with OA-induced NF-UB DNA binding activ-
ity, silymarin completely suppressed NF-UB-dependent gene
expression with concentrations as low as 12.5 Wg/ml (Fig.
4A). The basal luciferase activity was also notably reduced
(Fig. 4A and B). Further, silymarin (25 Wg/ml) e⁄ciently in-
hibited LPS-induced NF-UB-dependent gene expression (data
not shown). However, silymarin had no signi¢cant e¡ect on
NF-UB-dependent gene expression induced by TNFK or PMA
(Fig. 4B and data not shown).
4. Discussion
NF-UB-dependent gene expression patterns were found to
be di¡erent between the two groups of inducers evaluated:
OA and LPS in one group, TNFK and PMA in another.
The same distinction was also noticed in the ability of sily-
marin to suppress both NF-UB DNA-binding activity and its
dependent gene expression. Thus, we demonstrate the co-ex-
istence of two activating pathways in HepG2 cells : one that is
highly sensitive to silymarin and one that is non-responsive to
this inhibitor.
4.1. NF-UB activating pathways
The inducers used in the present study belong to distinct
classes of NF-UB stimuli. OA is a serine/threonine phospha-
tase (PP1 and PP2A) inhibitor which has been shown to acti-
vate NF-UB [17], possibly by blocking PP2A-induced IUB kin-
ase (IKK) inactivation in HeLa cells [18]. TNFK-induced NF-
UB activation has been extensively studied and revealed sev-
eral proteins mediating its e¡ect from the membrane receptor
to the newly identi¢ed IKK kinase complex ([19] and refer-
ences therein). Accordingly, their signaling pathways appear
to converge at the IUB phosphorylation step.
At least two lines of evidence are found in the literature
demonstrating that, in a given cell line, NF-UB is activated via
di¡erent pathways. First, two defective mutant cell lines have
been shown as responsive only to a subset of stimuli [20,21].
In addition, some, but not all, of these stimuli induce NF-UB
activation using a pathway that is insensitive to the action of
the antioxidant and metal chelator pyrrolidine dithiocarba-
mate (PDTC) [20,21]. Second, in Jurkat T-cells, OA was
found to induce NF-UB activation via an antioxidant-insensi-
tive pathway [22,23]. Similarly, the processing of p105, NF-UB
precursor, induced by PMA/ionomycin was not a¡ected by
PDTC in the same cell line [24].
In HepG2 cells, silymarin was unable to block TNFK-in-
duced NF-UB activation. However, in the Wuºrzburg subclone
of Jurkat T-cells treated with TNFK, silymarin exhibited a
potent inhibitory e¡ect (C. Saliou, unpublished observations)
at concentrations similar to those blocking OA- or LPS-in-
duced NF-UB activation in HepG2. Comparable observations
have been made where the inhibition by PDTC is cell-speci¢c
[25].
While IUBK appears to be the main regulator of TNFK-
induced NF-UB activation in most of the cells, Han and Bras-
ier demonstrated a key role for IUBL in the second phase of
NF-UB activation by TNFK [26]. This particularity could ex-
plain the non-responsiveness of TNFK-induced NF-UB activa-
tion to silymarin in HepG2 but not in Wuºrzburg cells.
4.2. Potential silymarin-sensitive steps in NF-UB activating
cascades
Reactive oxygen intermediates are proposed to be involved
in NF-UB activation, though their target is still unknown (see
[2] and references therein). Likewise, many antioxidants exert
an inhibitory action on NF-UB activation [27]. Silymarin, like
most antioxidants, is a reducing agent due to its hydrogen and
electron donating properties. Concentrations of silymarin sim-
ilar to those used herein have been shown to e⁄ciently pre-
vent GSH depletion in HepG2 cells challenged by an oxida-
tive stress induced by high concentrations of acetaminophen
[9]. This preventive e¡ect could maintain the cellular reducing
potential, thus rendering them less sensitive to the action of
reactive oxygen intermediates. Whether the antioxidant activ-
ity of silymarin is responsible for the action reported herein is
challenged by con£icting reports. First, greater concentrations
of silibinin, the most active component of silymarin extract,
than the concentrations used in the present study may
be necessary to scavenge free radicals such as superoxide
[11]. Second, the AP-1 DNA binding activity, not a¡ected
by silymarin (data not shown), has been suggested to be
induced by antioxidants [28]. Third, in Jurkat T-cells [22,23]
and certain mutant cell lines [20,21] but not in HeLa cells
[29], OA-induced NF-UB activation is insensitive to antioxi-
dants.
Other targets of silymarin may include kinases and/or phos-
phatases that regulate NF-UB activity. In that respect, sily-
marin has been shown to block the epidermal growth factor
(EGF)-receptor-associated tyrosine kinase activity in the epi-
dermoid carcinoma cell line A431 [30]. Nevertheless, to date,
there is no indication that EGF-receptor signal transduction is
involved in NF-UB activation. Other £avonoids, genistein and
quercetin, have been reported to inhibit NF-UB activation by
blocking the tyrosine phosphorylation [4,31]. In another
study, evidence was presented where okadaic acid induced
the tyrosine phosphorylation of a cellular protein thought to
have a role in NF-UB activation [32]. Ultraviolet radiation has
also been reported to increase tyrosine phosphorylation [33]
and in a previous study [34], silymarin was also found to be
particularly e¡ective at blocking UV-induced NF-UB DNA
binding activity and its dependent gene expression in a human
keratinocyte cell line as well. However, whether silymarin
blocks a tyrosine phosphorylation-dependent step in NF-UB
activation or acts through its antioxidant properties are only
the possible explanations of the mechanisms of the inhibition
that are currently being investigated.
4.3. Conclusion
The present investigation demonstrates that silymarin exerts
a selective, but speci¢c, inhibitory action on NF-UB activation
according to the stimulus, thus con¢rming that di¡erent stim-
uli induce NF-UB activation via distinct pathways.
The results of this study also contribute to the understand-
ing of how silymarin protects against liver intoxication since
NF-UB activation is its target.
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